Process for preparing uracil derivatives
    1.
    发明授权
    Process for preparing uracil derivatives 失效
    制备尿嘧啶衍生物的方法

    公开(公告)号:US5286861A

    公开(公告)日:1994-02-15

    申请号:US928507

    申请日:1992-08-21

    CPC分类号: C07D239/54 C07D239/60

    摘要: The present invention relates to a novel process for preparing uracil derivatives useful as intermediates in the synthesis of uridines having antiviral or antitumor activity or useful as coadjuvants in antiviral therapy, characterized by converting a compound of the formula II into its mesylate derivative of the formula III which is the reduced to give the desired compound of the formula I: ##STR1## in which R.sub.1 is H, halogen, alkyl, aryl or aralkyl.

    摘要翻译: 本发明涉及一种制备尿嘧啶衍生物的新方法,其用作合成具有抗病毒或抗肿瘤活性的尿苷的中间体或用作抗病毒治疗中的辅佐剂,其特征在于将式(II)的化合物转化成式(II)的甲磺酸酯衍生物 III),其是还原得到所需的式(I)化合物,其中R 1是H,卤素,烷基,芳基或芳烷基。

    Process for the preparation of 9-amino camptothecin
    2.
    发明授权
    Process for the preparation of 9-amino camptothecin 失效
    制备9-氨基喜树碱的方法

    公开(公告)号:US06403603B1

    公开(公告)日:2002-06-11

    申请号:US08284129

    申请日:1994-08-02

    IPC分类号: C07D49122

    CPC分类号: C07D491/22

    摘要: 9-Amino-20(S)-camptothecin (I) is prepared by reducing 12-nitro-20(S)-camptothecin (II); converting the resulting 12-amino-20(S)-camptothecin (III) into a compound of formula (IV) wherein X is a group which can be reductively removed; reacting the compound of formula (IV) with a nitrating agent, to obtain thereby the corresponding 9-nitro-20(S)-camptothecin compound of formula (V) substituted at the 12-position by the group X; reducing in a single step the compound of formula (V), so obtaining the 9-amino-20(S)-camptothecin of formula (I); or reducing the compound of formula (V), so obtaining the corresponding 9-amino-20(S)-camptothecin compound of formula (VI) substituted at the 12-position by the group X and reductively removing the X group from the compound of formula (VI), so obtaining 9-amino-20(S)-camptothecin.

    摘要翻译: 通过还原12-硝基-20(S) - 喜树碱(II)制备9-氨基-20(S) - 喜树碱(I) 将所得的12-氨基-20(S) - 喜树碱(III)转化成式(IV)的化合物,其中X是可被还原去除的基团; 使式(Ⅳ)化合物与硝化剂反应,由此获得在X-12位被12位取代的相应的9-硝基-20(S)喜树碱化合物。 在一步中还原式(Ⅴ)化合物,从而得到式(I)的9-氨基-20(S) - 喜树碱; 或降低式(Ⅴ)化合物,从而得到在X基上被12位取代的相应的式(Ⅵ)的9-氨基-20(S) - 喜树碱化合物,并将X基团从 式(VI),因此得到9-氨基-20(S) - 喜树碱。

    Process for the preparation of substituted benzofuran derivatives
    3.
    发明授权
    Process for the preparation of substituted benzofuran derivatives 失效
    取代苯并呋喃衍生物的制备方法

    公开(公告)号:US5459161A

    公开(公告)日:1995-10-17

    申请号:US78293

    申请日:1993-06-25

    摘要: Substituted benzofuran derivatives of the formula (I): ##STR1## wherein one of R.sub.1 and R.sub.2 is hydrogen or halogen and the other is, independently, an amino group or a C.sub.2 -C.sub.4 alkanoyl amino group; R.sub.3 is hydrogen; a linear or branched C.sub.1 -C.sub.4 alkyl, C.sub.1 -C.sub.4 alkoxy or C.sub.2 -C.sub.4 alkoxycarbonyl group; halogen; or phenyl unsubstituted or substituted by a C.sub.1 -C.sub.4 alkyl group; A is a group --(CH.sub.2).sub.n -Het wherein Het is an optionally substituted heteromonocyclic or heterobicyclic ring containing one or two nitrogen atoms, and n is zero or an integer of 1 to 3; and the symbol ..... represents a single or double bond; may be prepared by a process comprising reacting a compound of formula II: ##STR2## in which L is a leaving group and R.sub.4 is hydrogen or a carboxy protecting group, with a compound of formula III;R'.sub.3 --C.dbd.C--R'.sub.3 IIIto obtain a compound of formula IV; ##STR3## which is then cyclized to obtain a compound of formula V; ##STR4## which is reacted with a compound of formula VI;H.sub.2 N--A VI.

    摘要翻译: PCT No.PCT / EP91 / 02512 Sec。 371日期:1993年6月25日 102(e)日期1993年6月25日PCT 1991年12月27日PCT PCT。 出版物WO92 / 12147 日本时间1992年7月23日。式(I)的取代苯并呋喃衍生物:其中R 1和R 2之一是氢或卤素,另一个独立地是氨基或C 2 -C 4烷酰基氨基; R3是氢; 直链或支链C 1 -C 4烷基,C 1 -C 4烷氧基或C 2 -C 4烷氧基羰基; 卤素; 或未被取代或被C 1 -C 4烷基取代的苯基; A是基团 - (CH 2)n -Het,其中Het是含有一个或两个氮原子的任选取代的杂单环或杂双环,且n为0或1至3的整数; 符号.....表示单键或双键; 可以通过包括使式II化合物:其中L是离去基团且R4是氢或羧基保护基的式II化合物与式III化合物反应来制备; R'3-C = C-R'3 III,得到式Ⅳ化合物; IV,然后将其环化以获得式V化合物; 其与式VI化合物反应; H2N-A VI。

    Amidino-camptothecin derivatives
    6.
    发明授权
    Amidino-camptothecin derivatives 失效
    脒基喜树碱衍生物

    公开(公告)号:US6093721A

    公开(公告)日:2000-07-25

    申请号:US269177

    申请日:1999-05-13

    CPC分类号: C07D491/22

    摘要: A water soluble camptothecin derivative which is 20(S)-7-ethyl-9(N-methyl-N-phenyl)amidino-camptothecin and pharmaceutically acceptable salts thereof, pharmaceutical compositions containing them and a process for their preparation are described. The compound of the invention and its pharmaceutically acceptable salts are useful antitumor agents and are further charactcrised by having a remarkable therapeutic index.

    摘要翻译: PCT No.PCT / EP98 / 04919 371日期1999年5月13日 102(e)日期1999年5月13日PCT提交1998年7月20日PCT公布。 公开号WO99 /​​ 05103 日期1999年2月4日为20(S)-7-乙基-9(N-甲基-N-苯基)脒基喜树碱及其药学上可接受的盐的水溶性喜树碱衍生物,含有它们的药物组合物及其制备方法 被描述。 本发明的化合物及其药学上可接受的盐是有用的抗肿瘤剂,并且通过具有显着的治疗指数进一步表征。

    9,10 disubstituted camptothecin derivatives with antitumor activity
    9.
    发明授权
    9,10 disubstituted camptothecin derivatives with antitumor activity 失效
    9,10具有抗肿瘤活性的二取代喜树碱衍生物

    公开(公告)号:US5998426A

    公开(公告)日:1999-12-07

    申请号:US913855

    申请日:1997-09-29

    CPC分类号: C07D491/22

    摘要: The present invention relates to 9-amino-10-(1-naphthylsulfonyloxy)-20(S)-camptothecin, 9-amino-10-phenylsulfonyloxy-20(S)-camptothecin, 7-ethyl-9-amino-10-(p-toluensulfonyloxy)-20(S)-camptothecin, their pharmaceutically acceptable salts, a process for their preparation, pharmaceutically compositions comprising them and their use as antitumor agents.

    摘要翻译: PCT No.PCT / EP97 / 00194 Sec。 371日期:1997年9月29日 102(e)1997年9月29日PCT PCT 1997年1月11日PCT公布。 出版物WO97 / 28164 日期:1997年8月7日本发明涉及9-氨基-10-(1-萘磺酰氧基)-20(S) - 喜树碱,9-氨基-10-苯基磺酰氧基-20(S) - 喜树碱,7-乙基-9- 氨基-10-(对甲苯磺酰氧基)-20(S) - 喜树碱,它们的药学上可接受的盐,其制备方法,包含它们的药物组合物及其作为抗肿瘤剂的用途。

    Substituted camptothecin derivatives and process for their preparation

    公开(公告)号:US5856333A

    公开(公告)日:1999-01-05

    申请号:US776192

    申请日:1997-01-27

    CPC分类号: C07D491/22

    摘要: The present invention relates to substituted camptothecin derivatives of formula (I) wherein the symbol - - - - represents a single or double bond; R.sub.1, R.sub.2 and R.sub.3 are as defined under (a) or (b) below: (a) R.sub.1 and R.sub.2 are, each independently, hydrogen; C.sub.1 -C.sub.4 alkyl; C.sub.3 -C.sub.7 cycloalkyl; phenyl C.sub.1 -C.sub.6 alkyl; an optionally substituted phenyl ring; --NR.sub.5 R.sub.6 wherein one of R.sub.5 and R.sub.6 is hydrogen, C.sub.1 -C.sub.6 alkyl or benzyl and the other is hydrogen, C.sub.1 -C.sub.6 alkanoyl, an optionally substituted C.sub.1 -C.sub.6 alkoxycarbonyl, an optionally substituted benzoyl, phenyl C.sub.1 -C.sub.6 alkanoyl, an optionally substituted C.sub.1 -C.sub.6 alkoxycarbonyl, an optionally substituted phenoxycarbonyl or phenyl C.sub.1 -C.sub.6 alkoxycarbonyl, or R.sub.5 and R.sub.6, combined together with the nitrogen atom to which they are linked, form a 4-7 membered saturated, optionally substituted, heteromonocyclic ring residue; COOR.sub.8 wherein R.sub.8 is hydrogen, C.sub.1 -C.sub.6 alkyl, C.sub.3 -C.sub.7 cycloalkyl or phenyl C.sub.1 -C.sub.6 alkyl; or COR.sub.9 wherein Rg is C.sub.1 -C.sub.6 alkyl, C.sub.3 -C.sub.7 cycloalkyl, phenyl C.sub.1 -C.sub.6 alkyl, an optionally substituted phenyl ring or NR.sub.10 R.sub.11 wherein R.sub.10 and R.sub.11 are, each independently, hydrogen or C.sub.1 -C.sub.6 alkyl; and R.sub.3 is hydrogen, C.sub.1 -C.sub.6 alkyl or an optionally substituted phenyl ring; or (b) R.sub.1 and R.sub.3, combined together, form a 5-8 membered, optionally substituted, carbomonocyclic ring, and R.sub.2 is hydrogen, C.sub.1 -C.sub.4 alkyl or C.sub.3 -C.sub.7 cycloalkyl; R.sub.4 is hydrogen, C.sub.1 -C.sub.6 alkyl, C.sub.3 -C.sub.7 cycloalkyl or phenyl C.sub.1 -C.sub.6 alkyl; X is hydrogen,C.sub.1 -C.sub.6 alkyl, C.sub.3 -C.sub.7 cycloalkyl, C.sub.1 -C.sub.6 alkoxy, C.sub.3 -C.sub.7 cycloalkoxy, C.sub.1 -C.sub.6 alkanoyloxy, benzoyloxy, amino, hydroxy, nitro, halogen or it is a methylenedioxy group linked to the positions 10 and 11 of the molecule, and the pharmaceutically acceptable salts thereof. The compounds according to the invention are useful in therapy as antitumor agents. ##STR1##